Company intelligence / Profile preview

Neuro Event Labs

Ownership: Private
Development stage: Commercial

Overview

The company’s main product, Nelli®, uses AI to analyze audio/video recordings for motor seizures. Clinical studies show high sensitivity for detecting convulsive seizures (95.2%) and all motor seizures (88%), with significant impact on clinical decision-making (>86% of cases) and therapeutic interventions or adjustments in 68% of monitored patients. The technology has been validated against gold-standard VEEG in large patient cohorts. Used both at home and in hospitals.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapySoftware/AI-based diagnostics
Industry: Physiological Monitoring

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Neuro Event Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuro Event Labs.

Explore the full profile